Peptide therapy claims on TikTok: what the science supports

What's this video probably claiming?

Michael Ward, NP, is likely responding to another creator's question about peptide therapy, probably covering one or more of the popular compounds in this space: BPC-157 for tissue repair, TB-500 for recovery, CJC-1295 or ipamorelin for growth hormone stimulation, or GHK-Cu for skin and anti-aging effects. Nurse practitioners in the peptide space tend to frame these compounds as underutilized clinical tools sitting at the intersection of regenerative medicine and performance optimization. The reply format suggests he's correcting a misconception or validating something a physician said, which is a common dynamic on TikTok health content. Expect claims about accelerated healing timelines, growth hormone pulse optimization, or anti-inflammatory mechanisms. The 21K views suggest this hit a receptive audience already primed to believe peptides are a suppressed or overlooked category of medicine.

What does the science actually show?

The honest answer is: it depends heavily on which peptide you're talking about, and the evidence ladder varies wildly. BPC-157 has the most preclinical depth, with rat studies showing accelerated tendon and gut healing, but zero completed human RCTs as of 2024. TB-500 (thymosin beta-4) has more legitimate roots, with a phase II trial by RegeneRx Biopharmaceuticals showing wound healing improvement, but that was topical application in a specific patient population. CJC-1295 with DAC does increase IGF-1 levels in humans. Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) showed sustained GH elevation across multiple doses, but the long-term metabolic implications of chronic GH stimulation are not established in healthy adults. MK-677, technically a ghrelin mimetic and not a peptide, does raise GH and IGF-1, but Nass et al. (2008, Annals of Internal Medicine) documented fluid retention, insulin resistance, and increased fasting glucose in older adults at 25mg daily. The human data is thinner than social media would have you believe.

Where does the social media noise diverge from clinical reality?

The biggest gap is the extrapolation from rodent studies to human outcomes. BPC-157 is essentially a rat experiment that became a human intervention trend without the intermediate steps. Creators often present the mechanism of action, say, upregulation of growth hormone receptors or nitric oxide modulation, as if mechanism equals clinical outcome. It does not. Dosing is another problem. Most TikTok content references doses pulled from bodybuilding forums, not clinical pharmacokinetics. The compounded peptides being injected by patients outside clinical supervision vary in purity, endotoxin levels, and actual peptide content. A 2023 FDA analysis of compounded peptide vials found significant variability in labeled versus actual concentrations. Stacking multiple peptides, a common recommendation in this content category, has essentially no safety data in humans. The receptor cross-talk between simultaneous GHRH analogs and ghrelin mimetics is not a studied clinical protocol.

What should you actually know?

Some peptides have legitimate, if early-stage, research behind them. GHK-Cu has published human data on wound healing and skin collagen synthesis, with Leyden et al. documenting measurable dermal changes. Semax and selank, nootropic peptides developed in Russia, have small controlled trials but almost no English-language peer-reviewed replication. The regulatory reality matters here: the FDA removed several peptides, including BPC-157 and TB-500, from the bulk compounding list in 2023, meaning legal access through licensed telehealth compounders is now restricted. Any platform or provider still offering these specific compounds should be explaining that legal and regulatory context clearly to patients. If a video does not mention FDA status, compounding pharmacy oversight, or the absence of human trial data, that is a red flag regardless of the creator's credentials. Nurse practitioners can prescribe, but prescribing authority does not equal clinical evidence.